Molecular Imaging in Cancer
Abstract
Medical imaging technologies have undergone explosive growth over the past few decades and now play a central role in clinical oncology. But the truly transformative power of imaging in the clinical management of cancer patients lies ahead. Today, imaging is at a crossroads, with molecularly targeted imaging agents expected to broadly expand the capabilities of conventional anatomical imaging methods. Molecular imaging will allow clinicians to not only see where a tumor is located in the body, but also to visualize the expression and activity of specific molecules (e.g., proteases and protein kinases) and biological processes (e.g., apoptosis, angiogenesis, and metastasis) that influence tumor behavior and/or response to therapy. This information is expected to have a major impact on cancer detection, individualized treatment, and drug development, as well as our understanding of how cancer arises.
Get full access to this article
View all available purchase options and get full access to this article.
Already a Subscriber?Sign In
References and Notes
1
M. E. Juweid, B. D. Cheson, N. Engl. J. Med.354, 496 (2006).
2
R. Weissleder, Nat. Rev. Cancer2, 11 (2002).
3
F. A. Jaffer, R. Weissleder, JAMA293, 855 (2005).
4
R. Etzioni et al., Nat. Rev. Cancer3, 243 (2003).
5
A. Sweet-Cordero et al., Nat. Genet.37, 48 (2005).
6
J. Grimm et al., Proc. Natl. Acad. Sci. U.S.A.102, 14404 (2005).
7
K. Marten et al., Gastroenterology122, 406 (2002).
8
H. Alencar, U. Mahmood, Y. Kawano, T. Hirata, R. Weissleder, Neoplasia7, 977 (2005).
9
J. A. Evans, N. S. Nishioka, Curr. Opin. Gastroenterol.21, 578 (2005).
10
M. G. Harisinghani et al., N. Engl. J. Med.348, 2491 (2003).
11
A. Quon, S. S. Gambhir, J. Clin. Oncol.23, 1664 (2005).
12
U. Guller et al., Breast Cancer Res. Treat.71, 171 (2002).
13
H. A. Wieder et al., J. Clin. Oncol.22, 900 (2004).
14
N. Avril et al., J. Clin. Oncol.23, 7445 (2005).
15
G. J. Kelloff, C. C. Sigman, Eur. J. Cancer41, 491 (2005).
16
The Biomedical Research and Development Guide is available at (www.biag.org/BIAG/rd.htm).
17
T. J. Lynch et al., J. Med.350, 2129 (2004).
18
J. W. Park et al., Clin. Cancer Res.10, 3885 (2004).
19
M. Rudin, R. Weissleder, Nat. Rev. Drug Discov.2, 123 (2003).
20
T. F. Massoud, S. S. Gambhir, Genes Dev.17, 545 (2003).
21
R. Weissleder, V. Ntziachristos, Nat. Med.9, 123 (2003).
22
S. Gross, D. Piwnica-Worms, Cancer Cell7, 5 (2005).
23
H. R. Herschman, Science302, 605 (2003).
24
P. R. Contag, Drug Discov. Today7, 555 (2002).
25
K. D. Wu et al., Proc. Natl. Acad. Sci. U.S.A.102, 10640 (2005).
26
K. Shah, C. H. Tung, X. O. Breakefield, R. Weissleder, Mol. Ther.11, 926 (2005).
27
G. Lappin, R. C. Garner, Nat. Rev. Drug Discov.2, 233 (2003).
28
A. Saleem et al., J. Clin. Oncol.19, 1421 (2001).
29
D. J. Propper et al., J. Clin. Oncol.21, 203 (2003).
30
Information on IND studies is available at (www.fda.gov/cder/guidance/7086fnl.htm).
31
V. Ntziachristos, A. G. Yodh, M. Schnall, B. Chance, Proc. Natl. Acad. Sci. U.S.A.97, 2767 (2000).
32
E. Nadler, B. Eckert, P. J. Neumann, Oncologist11, 90 (2006).
33
S. Heinrich et al., Ann. Surg.242, 235 (2005).
34
H. C. Kolb, K. B. Sharpless, Drug Discov. Today8, 1128 (2003).
35
J. A. Joyce et al., Cancer Cell4, 393 (2003).
36
D. G. Anderson, S. Levenberg, R. Langer, Nat. Biotechnol.22, 863 (2004).
37
R. Weissleder, K. Kelly, E. Y. Sun, T. Shtatland, L. Josephson, Nat. Biotechnol.23, 1418 (2005).
38
T. J. Meade, A. K. Taylor, S. R. Bull, Curr. Opin. Neurobiol.13, 597 (2003).
39
M. Querol, J. W. Chen, R. Weissleder, A. J. Bogdanov, Org. Lett.7, 1719 (2005).
40
R. Weissleder, C. H. Tung, U. Mahmood, A. Bogdanov Jr., Nat. Biotechnol.17, 375 (1999).
41
V. Ntziachristos, J. Ripoll, L. V. Wang, R. Weissleder, Nat. Biotechnol.23, 313 (2005).
42
M. Keller et al., Biol. Psychiatry59, 216 (2006).
43
The author is a founder of and holds shares of stock in VisEn Medical, a company that is developing experimental imaging technologies. The author thanks U. Mahmood, M. Harisinghani, and R. Hargreaves for figures and all members of the Center for Molecular Imaging Research for many helpful discussions.
Information & Authors
Information
Published In
Science
Volume 312 | Issue 5777
26 May 2006
26 May 2006
Copyright
American Association for the Advancement of Science.
Submission history
Published in print: 26 May 2006
Authors
Metrics & Citations
Metrics
Article Usage
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.
Cited by
- Imaging in drug development, Atkinson's Principles of Clinical Pharmacology, (343-358), (2022).https://doi.org/10.1016/B978-0-12-819869-8.00022-7
- Big Data analytics in medical imaging, Applications of Big Data in Healthcare, (113-136), (2021).https://doi.org/10.1016/B978-0-12-820203-6.00006-0
- Ultra-high-frequency radio-frequency acoustic molecular imaging with saline nanodroplets in living subjects, Nature Nanotechnology, 16, 6, (717-724), (2021).https://doi.org/10.1038/s41565-021-00869-5
- Photoacoustic Imaging and Photothermal Therapy of Semiconducting Polymer Nanoparticles: Signal Amplification and Second Near‐Infrared Construction, Small, 17, 6, (2004723), (2021).https://doi.org/10.1002/smll.202004723
- Bone-targeting polymer vesicles for simultaneous imaging and effective malignant bone tumor treatment, Biomaterials, 269, (120345), (2021).https://doi.org/10.1016/j.biomaterials.2020.120345
- Recent progress in targeted delivery vectors based on biomimetic nanoparticles, Signal Transduction and Targeted Therapy, 6, 1, (2021).https://doi.org/10.1038/s41392-021-00631-2
- Nanotechnology‐Based Strategies to Evaluate and Counteract Cancer Metastasis and Neoangiogenesis, Advanced Healthcare Materials, 10, 10, (2002163), (2021).https://doi.org/10.1002/adhm.202002163
- Focused Ultrasound-Augmented Cancer Phototheranostics Using Albumin–Indocyanine Green Nanoparticles, Ultrasound in Medicine & Biology, 47, 7, (1801-1813), (2021).https://doi.org/10.1016/j.ultrasmedbio.2021.02.026
- Aza-BODIPY encapsulated polymeric nanoparticles as an effective nanodelivery system for photodynamic cancer treatment, Materials Chemistry Frontiers, 5, 5, (2283-2293), (2021).https://doi.org/10.1039/D0QM00891E
- Recent advances in iron oxide nanoparticles for brain cancer theranostics: from in vitro to clinical applications , Expert Opinion on Drug Delivery, 18, 7, (949-977), (2021).https://doi.org/10.1080/17425247.2021.1888926
- See more
Loading...
View Options
Get Access
Log in to view the full text
AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.
- Become a AAAS Member
- Activate your AAAS ID
- Purchase Access to Other Journals in the Science Family
- Account Help
Log in via OpenAthens.
Log in via Shibboleth.
More options
Purchase digital access to this article
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
View options
PDF format
Download this article as a PDF file
Download PDF